Abstract Library

#2730 FOLFIRINEC, A Multi-Center, Randomized, Comparative Phase II Study of FOLFIRINOX vs Platinum-Etoposide as First Line Treatment for Metastatic Neuroendocrine Carcinoma of Gastroenteropancreatic or Unknown Origin, Associated with Molecular Profiling

Introduction: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine carcinoma (NEC) are rare diseases with a poor prognosis. FOLFIRINEC is a multicenter comparative phase II study of mFOLFIRINOX vs platinum-etoposide (PE) as first line treatment for metastatic G3 NEC of GEP or unknown origin.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hadoux J

Authors: Hadoux J, Afchain P, Walter T, Tougeron D, Hautefeuille V,

Keywords: neuroendocrine carcinoma, gastroenteropancreatic, chemotherapy, FOLFIRINOX, RB,

#1227 Molecular Profiling of Small Intestinal Neuroendocrine Tumours (SINETs)

Introduction: Aberrant DNA methylation plays an role in the pathogenesis of many cancers, however little is known about its role in SINET development.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Thirlwell C

Authors: Karpathakis A, Feber A, Morris T, Dibra H, Pipinikas C,

Keywords: Epigenetics, methylation, GIPR, biomarker,

#1059 Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in Precision-Medicine Era

Introduction: We have conducted molecular profiling through high-throughput molecular test as part of clinical practice for patients with advanced gastrointestinal (GI) cancer, or rare cancer including gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Park Y

Authors: Kim S, Yoo K, Jung K, Lee S, Lee J,

Keywords: molecular profiling, GEP-NET,

#722 Isolation and Whole Genome Amplification of Single Circulating Tumor Cells in Neuroendocrine Tumors: A Pilot Study

Introduction: We have previously demonstrated that Circulating Tumor Cells (CTCs) can be detected in patients with neuroendocrine tumors (NET) and that their presence is prognostic. Downstream analysis of CTCs provides an opportunity to explore their potential as biomarker for targeted therapy. Here we present initial data which demonstrates that molecular profiling can be successfully performed on single CTCs from patients with NETs

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Mandair D, Karpathakis A, Lowe H, Griffin N, Caplin M,

Keywords: circulating tumor cells, biomarker,